According to Johnson & Johnson, the late stage COVID-19 vaccine study has been fully enrolled

Its Jannsen unit plans to file an emergency use authorization application with the U.S. Food and Drug Administration (FDA) in February

Johnson & Johnson said Thursday that it has fully enrolled participants for the first advanced stage study of its COVID-19 single-dose vaccine candidate.

The study, called Ensemble, has enrolled about 45,000 participants and is led by its Janssen unit, J&J said in a statement, adding that it expects provisional data from the study by the end of January 2021.

J&J also said it plans to file an emergency use authorization application with the U.S. Food and Drug Administration (FDA) in February if the study data is safe and effective.

A separate late-stage clinical trial of an experimental COVID-19 vaccine candidate from Janssen to explore a two-dose regimen was underway, J&J said.

The Ensemble study was suspended for over a week in October after a patient developed an “unexplained illness” during the study. The company later said it would resume the process after an evaluation found no clear cause of the disease.

You have reached your limit of free articles this month.

Benefits of membership include

Today’s newspaper

Find the mobile-friendly version of daily newspaper articles in an easy-to-read list.

Unlimited access

Enjoy reading all the articles you want without limitations.

Personalized recommendations

A hand-picked list of items that match your interests and tastes.

Faster pages

Move smoothly between articles as our pages load instantly.

Control panel

A one stop shop to view the latest updates and manage your preferences.

Meeting

We inform you about the latest and most important developments, three times a day.

Support quality journalism.

* Our digital subscription plans do not currently include e-paper, crossword puzzle and print.

Source